Management of Pediatric Guillain-Barré Syndrome
For children with suspected GBS, initiate intravenous immunoglobulin (IVIg) at 0.4 g/kg daily for 5 days as first-line therapy if the child is unable to walk unaided and is within 2 weeks of weakness onset 1, 2.
Diagnosis and Recognition
Clinical Features to Identify
- Rapidly progressive bilateral weakness starting in legs, progressing to arms and cranial muscles over hours to days
- Areflexia or hyporeflexia (though normal/exaggerated reflexes can occur in pure motor variants)
- Preceding infection in 50-62% of cases (respiratory or gastrointestinal illness 1-4 weeks prior) 3, 4
Pediatric-Specific Presentations (<6 years)
Young children often present atypically, making early recognition challenging 1:
- Poorly localized pain
- Refusal to bear weight or walk
- Irritability
- Meningism
- Unsteady gait
Critical pitfall: Failure to recognize these nonspecific signs causes diagnostic delays in young children 1.
Supportive Diagnostic Testing
- CSF analysis: Albuminocytologic dissociation (elevated protein, normal cell count) - valuable when diagnosis uncertain 5
- Nerve conduction studies: Support diagnosis but don't delay treatment
- Anti-GQ1b antibodies: Only if Miller Fisher syndrome suspected 5
Treatment Algorithm
First-Line Therapy: IVIg
IVIg is the preferred treatment for children over plasma exchange due to 1, 2:
- Easier administration
- Lower complication rates in pediatric patients
- Less discomfort
- Wider availability
Dosing regimen:
- 0.4 g/kg/day for 5 consecutive days (total 2 g/kg)
- Do NOT use 2-day regimen (2 g/kg over 2 days) - associated with higher treatment-related fluctuation rates (5/23 vs 0/23 children) 1
Indications for Treatment
Treat if:
- Unable to walk unaided (GBS disability scale ≥3)
- Within 2 weeks of weakness onset (strong recommendation)
- Consider treatment between 2-4 weeks if still progressing 5
Second-Line: Plasma Exchange
- IVIg intolerance or contraindication
- IVIg treatment failure
- Requires experienced center (200-250 mL/kg over 4-5 sessions)
What NOT to Do
- Do NOT use corticosteroids - proven ineffective and oral steroids may worsen outcome 1, 5
- Do NOT give second IVIg course for poor prognosis patients 5
- Do NOT combine plasma exchange followed by IVIg - no additional benefit 1
Monitoring Requirements
Respiratory Assessment (Critical)
Use the "20/30/40 rule" - patient at risk if 1:
- Vital capacity <20 mL/kg, OR
- Maximum inspiratory pressure <30 cmH₂O, OR
- Maximum expiratory pressure <40 cmH₂O
Additional respiratory monitoring:
- Single breath count ≤19 predicts need for mechanical ventilation 1
- Assess for accessory muscle use
- Monitor swallowing/coughing difficulties
Neurological Monitoring
- Muscle strength: Medical Research Council scale for neck, arms, legs
- Functional disability: GBS disability scale
- Autonomic function: ECG, heart rate, blood pressure, bowel/bladder function 1
Frequency
Monitoring intensity depends on deterioration rate - up to two-thirds of deaths occur during recovery phase from cardiovascular complications 1.
Prognostic Assessment
Calculate modified Erasmus GBS Outcome Score (mEGOS) on admission to predict outcome 1, 5.
Calculate Erasmus GBS Respiratory Insufficiency Score (EGRIS) to assess 1-week ventilation risk (1-90% probability) 1.
Expected Outcomes
- Complete recovery: 70% of children (14/20 in one series) 3
- Incomplete recovery: ~15%
- Respiratory failure requiring ventilation: 35% 3
- Recovery timeline: Can continue >3 years after onset 1
- Recurrence: Rare (2-5%) 1
Special Consideration: A-CIDP
Consider changing diagnosis to acute-onset CIDP if: